Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway

Frédéric Stauffer; Sauveur-Michel Maira; Pascal Furet; Carlos García-Echeverría

doi:10.1016/j.bmcl.2007.12.018

Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1027-30. doi: 10.1016/j.bmcl.2007.12.018. Epub 2007 Dec 15.

Authors

Frédéric Stauffer¹, Sauveur-Michel Maira, Pascal Furet, Carlos García-Echeverría

Affiliation

¹ Novartis Institute for BioMedical Research, Oncology Drug Discovery, Klybeckstrasse 141, Postfach, CH-4002 Basel, Switzerland. [email protected]

PMID: 18248814
DOI: 10.1016/j.bmcl.2007.12.018

Abstract

Imidazo[4,5-c]quinoline derivatives have been discovered and developed as potent and effective modulators of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) pathway to lead to clinical development candidates. The SAR data of representative examples of this compound class and their biological profiling in cellular and in vivo settings are presented and discussed.

MeSH terms

Animals
Imidazoles / chemical synthesis*
Imidazoles / chemistry
Imidazoles / pharmacology*
Mice
Mice, Nude
Molecular Structure
Phosphoinositide-3 Kinase Inhibitors*
Proto-Oncogene Proteins c-akt / antagonists & inhibitors*
Quinolines / chemical synthesis*
Quinolines / chemistry
Quinolines / pharmacology*
Structure-Activity Relationship

Substances

Imidazoles
Phosphoinositide-3 Kinase Inhibitors
Quinolines
Proto-Oncogene Proteins c-akt